Inflammopharmacology SCIE

国际简称：INFLAMMOPHARMACOLOGY 参考译名：炎症药理学

主要研究方向：IMMUNOLOGYTOXICOLOGY-TOXICOLOGY 非预警期刊审稿周期：

《炎症药理学》(Inflammopharmacology)是一本由Springer International Publishing出版的以IMMUNOLOGYTOXICOLOGY-TOXICOLOGY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本未开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

2区中科院分区
Q1 JCR分区
263 年发文量
4.6 IF影响因子
未开放 是否OA
45 H-index
1991 创刊年份
6 issues per year 出版周期
English 出版语言

Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:

-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states

-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs

-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents

-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain

-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs

-Muscle-immune interactions during inflammation [...]

[ 查看全部 ]

投稿咨询加急咨询

投稿热线：400-888-7501

Inflammopharmacology期刊信息

ISSN：0925-4692
出版语言：English
是否OA：未开放
E-ISSN：1568-5608
出版地区：NETHERLANDS
是否预警：否
出版商：Springer International Publishing
出版周期：6 issues per year
创刊时间：1991
开源占比：0.128
Gold OA文章占比：20.93%
OA被引用占比：0.0576...
出版国人文章占比：0.15
出版撤稿占比：0
研究类文章占比：65.78%

Inflammopharmacology CiteScore评价数据（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指数

0.952

1.006

学科类别	分区	排名	百分位
大类：Medicine 小类：Pharmacology (medical)	Q1	37 / 272	86%
大类：Medicine 小类：Pharmacology	Q1	70 / 313	77%
大类：Medicine 小类：Immunology	Q2	80 / 236	66%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Inflammopharmacology中科院评价数据

中科院 2023年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	2区	TOXICOLOGY 毒理学 IMMUNOLOGY 免疫学	1区 3区

中科院 2022年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	2区	IMMUNOLOGY 免疫学 TOXICOLOGY 毒理学	2区 2区

中科院 2021年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	IMMUNOLOGY 免疫学 TOXICOLOGY 毒理学	3区 3区

中科院 2021年12月基础版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	IMMUNOLOGY 免疫学 TOXICOLOGY 毒理学	3区 2区

中科院 2021年12月升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	IMMUNOLOGY 免疫学 TOXICOLOGY 毒理学	3区 3区

中科院 2020年12月旧的升级版

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	3区	IMMUNOLOGY 免疫学 TOXICOLOGY 毒理学	3区 3区

Inflammopharmacology JCR评价数据（2023-2024年最新版）

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：IMMUNOLOGY	SCIE	Q2	56 / 181	69.3%
学科：TOXICOLOGY	SCIE	Q1	17 / 106	84.4%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：IMMUNOLOGY	SCIE	Q1	37 / 181	79.83%
学科：TOXICOLOGY	SCIE	Q1	17 / 106	84.43%

Inflammopharmacology历年数据统计

影响因子

中科院分区

Inflammopharmacology中国学者发文选摘

1、Diosmetin alleviates acute lung injury caused by lipopolysaccharide by targeting barrier function
Author: Xia, Jiying; Li, Junhong; Deng, Mengsheng; Yin, Fei; Liu, Jianhui; Wang, Jianmin

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01228-7
2、Phytochemicals as potential target on thioredoxin-interacting protein (TXNIP) for the treatment of cardiovascular diseases
Author: Zhou, Peng; Ma, Yao-yao; Zhao, Xiao-ni; Hua, Fang

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-022-01130-8
3、Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury
Author: Liu, Yuanshui; Yang, Hang; Zhu, Fei; Ouyang, Yanhong; Pan, Pinhua

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01199-9
4、Adalimumab combined with erythropoietin improves recovery from spinal cord injury by suppressing microglial M1 polarization-mediated neural inflammation and apoptosis
Author: Liu, Yanming; Zhang, Feiyue; Sun, Qi; Liang, Lichao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 887-897. DOI: 10.1007/s10787-022-01090-z
5、Suprabasin-derived polypeptides: SBSN(50-63) induces inflammatory response via TLR4-mediated mast cell activation
Author: Zhou, Tong; Du, Xueshan; Zhang, Lei; Zheng, Yi; Jia, Tao; Song, Xiangjin; Che, Delu; Geng, Songmei

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01137-9
6、Synovial mesenchymal stem cell-derived exosomal microRNA-320c facilitates cartilage damage repair by targeting ADAM19-dependent Wnt signalling in osteoarthritis rats
Author: Kong, Ruina; Zhang, Ju; Ji, Lianmei; Yu, Yiyi; Gao, Jie; Zhao, Dongbao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 915-926. DOI: 10.1007/s10787-023-01142-y
7、A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis
Author: Guo, Haohao; Wang, Ziyang; Ma, Runsheng; Chen, Xin; Li, Hongqiang; Tang, Yifeng; Du, Gongbo; Zhang, Yifei; Yin, Detao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 745-754. DOI: 10.1007/s10787-023-01148-6
8、Daidzein attenuated paclitaxel-induced neuropathic pain via the down-regulation of TRPV1/P2Y and up-regulation of Nrf2/HO-1 signaling
Author: Zafar, Sana; Luo, Yong; Zhang, Li; Li, Chang Hu; Khan, Adnan; Khan, Muhammad Ibrar; Shah, Kifayatullah; Seo, Eun Kyoung; Wang, Feng; Khan, Salman

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01225-w